JW Shinyak Corp

JW Shinyak Corp maintains a strong capital structure with a debt-to-equity ratio of 0.08, indicating a conservative leverage position relative to industry norms. The company's liquidity is assessed as medium, with a current ratio of 1.69, suggesting it can cover short-term obligations but with limited excess cash. Free cash flow of 15,835,000,325 KRW supports operational flexibility, though net cash is negative after subtracting total debt. Profitability metrics show a return on equity (ROE) of 38.44% and a return on assets (ROA) of 26.88%, both significantly above the median for the Pharmaceuticals industry. These figures reflect strong asset utilization and efficient capital deployment. Gross profit of 40,115,595,990 KRW supports a healthy margin profile, though the company's operating income of 7,455,451,170 KRW is lower than gross profit, indicating some operational cost pressures. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic and regulatory shifts. No major international markets are reported, and the company's revenue is entirely attributed to domestic operations. Growth trajectory is mixed. Revenue of 81,043,717,130 KRW in the latest period shows a stable base, but the company's net income of 15,656,704,370 KRW is lower than gross profit, suggesting margin compression. Analyst estimates indicate a negative EPS of -352.74 KRW, signaling potential earnings pressure in the near term. Risk factors include liquidity constraints, as net cash is negative after subtracting total debt. The company's dilution risk is assessed as low, with no near-term pressure from share issuance. However, the absence of a robust cash buffer could limit flexibility in capital allocation or crisis response. Recent events include a negative EPS report, which may signal underlying operational or market challenges. No major regulatory or legal filings were disclosed in the latest period, but the company's exposure to domestic healthcare policy shifts remains a key risk.